---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-298979"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-07-09T10:00:22+00:00"
generated_at: "2026-07-09T10:05:24.152266+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics amends loan facility with Oxford Finance, extends Term A draw period to Dec 31, 2026

## Summary
- Amendment extends availability of remaining $15M Term A loans through Dec 31, 2026; upfront fee of $187,500.
- If full $15M not drawn by Dec 31, 2026, non-utilization fee of 1% of undrawn amount applies.
- If full $15M drawn, Term B loan availability extended to Sep 30, 2027; Term C loans restructured into two $20M tranches with revenue/clinical milestones.
- Minimum revenue covenants begin Q2 2027 or later depending on capital raises; original facility up to $150M with $25M drawn in Nov 2025.

## SEC filing metadata
- accession: 0001193125-26-298979
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-07-09T10:00:22+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/0001193125-26-298979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526298979/kytx-20260708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-298979
- JSON: https://secwatch.observer/filing/0001193125-26-298979.json
- Plain text: https://secwatch.observer/filing/0001193125-26-298979.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.